Localization of sunitinib in in vivo animal and in vitro experimental models by MALDI mass spectrometry imaging

James J. Connell, Yutaka Sugihara, Szilvia Török, B. Döme, J. Tóvári, Thomas E. Fehniger, György Marko-Varga, Ákos Végvári

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The spatial distribution of an anticancer drug and its intended target within a tumor plays a major role on determining how effective the drug can be at tackling the tumor. This study provides data regarding the lateral distribution of sunitinib, an oral antiangiogenic receptor tyrosine kinase inhibitor using an in vitro animal model as well as an in vitro experimental model that involved deposition of a solution of sunitinib onto tissue sections. All tumor sections were analyzed by matrix-assisted laser desorption/ionization mass spectrometry imaging and compared with subsequent histology staining. Six tumors at four different time points after commencement of in vivo sunitinib treatment were examined to observe the patterns of drug uptake. The levels of sunitinib present in in vivo treated tumor sections increased continuously until day 7, but a decrease was observed at day 10. Furthermore, the in vitro experimental model was adjustable to produce a drug level similar to that obtained in the in vivo model experiments. The distribution of sunitinib in tissue sections treated in vitro appeared to agree with the histological structure of tumors, suggesting that this approach may be useful for testing drug update.

Original languageEnglish
Pages (from-to)2245-2253
Number of pages9
JournalAnalytical and Bioanalytical Chemistry
Volume407
Issue number8
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Mass spectrometry
Tumors
Mass Spectrometry
Animals
Theoretical Models
Imaging techniques
Neoplasms
Pharmaceutical Preparations
Tissue
Histology
Receptor Protein-Tyrosine Kinases
Spatial distribution
Ionization
sunitinib
In Vitro Techniques
Desorption
Animal Models
Staining and Labeling
Lasers

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry

Cite this

Localization of sunitinib in in vivo animal and in vitro experimental models by MALDI mass spectrometry imaging. / Connell, James J.; Sugihara, Yutaka; Török, Szilvia; Döme, B.; Tóvári, J.; Fehniger, Thomas E.; Marko-Varga, György; Végvári, Ákos.

In: Analytical and Bioanalytical Chemistry, Vol. 407, No. 8, 01.03.2015, p. 2245-2253.

Research output: Contribution to journalArticle

Connell, James J. ; Sugihara, Yutaka ; Török, Szilvia ; Döme, B. ; Tóvári, J. ; Fehniger, Thomas E. ; Marko-Varga, György ; Végvári, Ákos. / Localization of sunitinib in in vivo animal and in vitro experimental models by MALDI mass spectrometry imaging. In: Analytical and Bioanalytical Chemistry. 2015 ; Vol. 407, No. 8. pp. 2245-2253.
@article{75e4447df48247c698be0aac3f20f35f,
title = "Localization of sunitinib in in vivo animal and in vitro experimental models by MALDI mass spectrometry imaging",
abstract = "The spatial distribution of an anticancer drug and its intended target within a tumor plays a major role on determining how effective the drug can be at tackling the tumor. This study provides data regarding the lateral distribution of sunitinib, an oral antiangiogenic receptor tyrosine kinase inhibitor using an in vitro animal model as well as an in vitro experimental model that involved deposition of a solution of sunitinib onto tissue sections. All tumor sections were analyzed by matrix-assisted laser desorption/ionization mass spectrometry imaging and compared with subsequent histology staining. Six tumors at four different time points after commencement of in vivo sunitinib treatment were examined to observe the patterns of drug uptake. The levels of sunitinib present in in vivo treated tumor sections increased continuously until day 7, but a decrease was observed at day 10. Furthermore, the in vitro experimental model was adjustable to produce a drug level similar to that obtained in the in vivo model experiments. The distribution of sunitinib in tissue sections treated in vitro appeared to agree with the histological structure of tumors, suggesting that this approach may be useful for testing drug update.",
author = "Connell, {James J.} and Yutaka Sugihara and Szilvia T{\"o}r{\"o}k and B. D{\"o}me and J. T{\'o}v{\'a}ri and Fehniger, {Thomas E.} and Gy{\"o}rgy Marko-Varga and {\'A}kos V{\'e}gv{\'a}ri",
year = "2015",
month = "3",
day = "1",
doi = "10.1007/s00216-014-8350-2",
language = "English",
volume = "407",
pages = "2245--2253",
journal = "Fresenius Zeitschrift fur Analytische Chemie",
issn = "1618-2642",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Localization of sunitinib in in vivo animal and in vitro experimental models by MALDI mass spectrometry imaging

AU - Connell, James J.

AU - Sugihara, Yutaka

AU - Török, Szilvia

AU - Döme, B.

AU - Tóvári, J.

AU - Fehniger, Thomas E.

AU - Marko-Varga, György

AU - Végvári, Ákos

PY - 2015/3/1

Y1 - 2015/3/1

N2 - The spatial distribution of an anticancer drug and its intended target within a tumor plays a major role on determining how effective the drug can be at tackling the tumor. This study provides data regarding the lateral distribution of sunitinib, an oral antiangiogenic receptor tyrosine kinase inhibitor using an in vitro animal model as well as an in vitro experimental model that involved deposition of a solution of sunitinib onto tissue sections. All tumor sections were analyzed by matrix-assisted laser desorption/ionization mass spectrometry imaging and compared with subsequent histology staining. Six tumors at four different time points after commencement of in vivo sunitinib treatment were examined to observe the patterns of drug uptake. The levels of sunitinib present in in vivo treated tumor sections increased continuously until day 7, but a decrease was observed at day 10. Furthermore, the in vitro experimental model was adjustable to produce a drug level similar to that obtained in the in vivo model experiments. The distribution of sunitinib in tissue sections treated in vitro appeared to agree with the histological structure of tumors, suggesting that this approach may be useful for testing drug update.

AB - The spatial distribution of an anticancer drug and its intended target within a tumor plays a major role on determining how effective the drug can be at tackling the tumor. This study provides data regarding the lateral distribution of sunitinib, an oral antiangiogenic receptor tyrosine kinase inhibitor using an in vitro animal model as well as an in vitro experimental model that involved deposition of a solution of sunitinib onto tissue sections. All tumor sections were analyzed by matrix-assisted laser desorption/ionization mass spectrometry imaging and compared with subsequent histology staining. Six tumors at four different time points after commencement of in vivo sunitinib treatment were examined to observe the patterns of drug uptake. The levels of sunitinib present in in vivo treated tumor sections increased continuously until day 7, but a decrease was observed at day 10. Furthermore, the in vitro experimental model was adjustable to produce a drug level similar to that obtained in the in vivo model experiments. The distribution of sunitinib in tissue sections treated in vitro appeared to agree with the histological structure of tumors, suggesting that this approach may be useful for testing drug update.

UR - http://www.scopus.com/inward/record.url?scp=85027937155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027937155&partnerID=8YFLogxK

U2 - 10.1007/s00216-014-8350-2

DO - 10.1007/s00216-014-8350-2

M3 - Article

C2 - 25424181

AN - SCOPUS:85027937155

VL - 407

SP - 2245

EP - 2253

JO - Fresenius Zeitschrift fur Analytische Chemie

JF - Fresenius Zeitschrift fur Analytische Chemie

SN - 1618-2642

IS - 8

ER -